Search - tctmd.com

Displaying 301 - 320 of 412

Sort: Relevancy | Date

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

L.A. McKeown

June 03, 2021

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

Todd Neale

May 18, 2021

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

L.A. McKeown

February 04, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

L.A. McKeown

February 01, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

L.A. McKeown

January 11, 2021

News Daily News

LAA Occlusion With Amplatzer Amulet May Have Edge Over DOACs

Todd Neale

January 08, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

Advertisement

Less Cancer Among HF Patients Taking Statins, Registry Shows

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

‘Enormous’ QoL Improvements With Mavacamten in HCM

FDA Approves Dapagliflozin for CKD Patients

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Did Regional Differences Muddy Results in COMMANDER-HF?

February 2021 News Roundup

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

FDA Approves Vericiguat for High-risk Patients With HF

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

LAA Occlusion With Amplatzer Amulet May Have Edge Over DOACs

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content